MGIM
JNCE

M&G Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

M&G Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-36,779
Closed -$257 – 797
2021
Q2 		$257 Buy
+36,779
New +$306K ﹤0.01% 709

Other funds holding JNCE

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

M&G Investment Management's JNCE Position: Q3 2021 in Review

M&G Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 36,779 shares — an estimated $257 sold.

M&G Investment Management first reported a position in JNCE in Q2 2021 and held it in 1 quarter. The position peaked at $257 in Q2 2021. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

  • M&G Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • M&G Investment Management sold 36,779 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $257.
  • M&G Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • M&G Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $257 in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on M&G Investment Management's 13F filing for Q3 2021, filed 9 Nov 2021.